Human dendritic cells transfected with amplified MUC1 mRNA stimulate cytotoxic T lymphocyte responses against pancreatic cancer in vitro

Journal of Gastroenterology and Hepatology (Australia)

Volumn 26, Issue 10, 2011, Pages 1509-1518

  Chen, Jiang ^a   Li, Hong Yu ^a   Wang, Di ^a   Zhao, Jia Jun ^a   Guo, Xiao Zhong ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Cancers: biology; Diagnosis and therapy; Pancreas; Pancreatic cancer

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MESSENGER RNA; MUCIN 1;

ANTIGEN PRESENTATION; ARTICLE; CHROMIUM 51 RELEASE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DENDRITIC CELL; ELECTROPORATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; INTERFERON GAMMA RELEASE ASSAY; NORMAL HUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ASSAY; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

EID: 80053119078     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2011.06778.x     Document Type: Article

References (33)

1. Jemal A, Siegel R, Ward E etal. Cancer statistics, 2009. CA Cancer J. Clin. 2009; 59: 225-49.
2. Philip PA, Mooney M, Jaffe D etal. Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment. J. Clin. Oncol. 2009; 27: 5660-9.
3. Hegmans JP, Veltman JD, Lambers ME etal. Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma. Am. J. Respir. Crit. Care Med. 2010; 181: 1383-90.
4. Toh HC, Wang WW, Chia WK etal. Clinical benefit of allogeneic melanoma cell lysate-pulsed autologous dendritic cell vaccine in MAGE-positive colorectal Cancer Patients. Clin. Cancer Res. 2009; 15: 7726-36.
5. Soleimani A, Berntsen A, Svane IM etal. Immune responses in patients with metastatic renal cell carcinoma treated with dendritic cells pulsed with tumor lysate. Scand. J. Immunol. 2009; 70: 481-9.
6. Zhang X, Gordon JR, Xiang J. Advances in dendritic cell-based vaccine of cancer. Cancer Biother. Radiopharm. 2002; 17: 601-19.
7. Fujii S, Takayama T, Asakura M etal. Dendritic cell-based cancer immunotherapies. Arch. Immunol. Ther. Exp. 2009; 57: 189-98.
8. Heiser A, Coleman D, Dannull J etal. Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J. Clin. Invest. 2002; 109: 409-17.
9. Von Mensdorff-Pouilly S, Snijdewint FG, Verstraeten AA etal. Human MUC1 mucin: a multifaceted glycoprotein. Int. J. Biol. Markers 2000; 15: 343-56.
10. Mukherjee P, Madsen CS, Ginardi AR etal. Mucin1-specific immunotherapy in a mouse model of spontaneous breast cancer. J. Immunother. 2003; 26: 47-62.
11. Wang K, Zhou Q, Guo AL etal. An autologous therapeutic dendritic cell vaccine transfected with total lung carcinoma RNA stimulates cytotoxic T lymphocyte responses against non-small cell lung cancer. Immunol. Invest. 2009; 38: 665-80.
12. Joshi MD, Ahmad R, Yin L etal. MUC1 oncoprotein is a druggable target in human prostate cancer cells. Mol. Cancer Ther. 2009; 8: 3056-65.
13. Dobrzanski MJ, Rewers-Felkins KA, Quinlin IS etal. Autologous MUC1-specific Th1 effector cell immunotherapy induces differential levels of systemic TReg cell subpopulations that result in increased ovarian cancer patient survival. Clin. Immunol. 2009; 133: 333-52.
14. Yonezawa S, Higashi M, Yamada N etal. Significance of mucin expression in pancreatobiliary neoplasms. J. Hepatobiliary Pancreat. Sci. 2010; 17: 108-24.
15. Tang CK, Apostolopoulos V. Strategies used for MUC1 immunotherapy: preclinical studies. Expert Rev. Vaccines 2008; 7: 951-62.
16. Tang CK, Katsara M, Apostolopoulos V. Strategies used for MUC1 immunotherapy: human clinical studies. Expert Rev. Vaccines 2008; 7: 963-75.
17. Sipos B, Möser S, Kalthoff H etal. A comprehensive characterization of pancreatic ductal carcinoma cell lines: towards the establishment of an in vitro research platform. Virchows Arch. 2003; 442: 444-52.
18. Zeis M, Siegel S, Wagner A etal. Generation of cytotoxic responses in mice and human individuals against hematological malignancies using survivin-RNA-transfected dendritic cells. J. Immunol. 2003; 170: 5391-7.
19. Prechtel AT, Steinkasserer A. CD83: an update on functions and prospects of the maturation marker of dendritic cells. Arch. Dermatol. Res. 2007; 299: 59-69.
20. Ma DY, Clark EA. The role of CD40 and CD154/CD40L in dendritic cells. Semin. Immunol. 2009; 21: 265-72.
21. Bhatia S, Edidin M, Almo SC etal. B7-1 and B7-2: similar costimulatory ligands with different biochemical, oligomeric and signaling properties. Immunol. Lett. 2006; 104: 70-5.
22. Arkusz J, Gradecka-Meesters D, Stepnik M. Interleukin-1beta and surface marker expression changes induced by tetrachloroplatinate in human monocyte-derived dendritic cells. Immunopharmacol. Immunotoxicol. 2010; 32: 37-46.
23. Dörfel D, Appel S, Grünebach F etal. Processing and presentation of HLA class I and II epitopes by dendritic cells after transfection with in vitro-transcribed MUC1 RNA. Blood 2005; 105: 3199-205.
24. Fujii S, Goto A, Shimizu K. Antigen mRNA-transfected, allogeneic fibroblasts loaded with NKT-cell ligand confer antitumor immunity. Blood 2009; 113: 4262-72.
25. Van Tendeloo VF, Ponsaerts P, Lardon F, Nijs G etal. Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells. Blood 2001; 98: 49-56.
26. Ohuchida K, Mizumoto K, Yamada D etal. Quantitative analysis of MUC1 and MUC5AC mRNA in pancreatic juice for preoperative diagnosis of pancreatic cancer. Int. J. Cancer 2006; 118: 405-11.
27. Heiser A, Maurice MA, Yancey DR etal. Induction of polyclonal prostate cancer-specific CTL using dendritic cells transfected with amplified tumor RNA. J. Immunol. 2001; 166: 2953-60.
28. Avigan D. Dendritic cells: development, function and potential use for cancer immunotherapy. Blood Rev. 1999; 13: 51-64.
29. Heiser A, Dahm P, Yancey DR etal. Human dendritic cells transfected with RNA encoding prostate-specific antigen stimulate prostate-specific CTL responses in vitro. J. Immunol. 2000; 164: 5508-14.
30. Torchilin VP. Recent approaches to intracellular delivery of drugs and DNA and organelle targeting. Annu. Rev. Biomed. Eng. 2006; 8: 343-75.
31. Michiels A, Tuyaerts S, Bonehill A etal. Delivery of tumor-antigen-encoding mRNA into dendritic cells for vaccination. Methods Mol. Biol. 2008; 423: 155-63.
32. Lesterhuis WJ, Aarntzen EH, De Vries IJ etal. Dendritic cell vaccines in melanoma: from promise to proof. Crit. Rev. Oncol. Hematol. 2008; 66: 118-34.
33. Kurotaki T, Tamura Y, Ueda G etal. Efficient cross-presentation by heat shock protein 90-peptide complex-loaded dendritic cells via an endosomal pathway. J. Immunol. 2007; 179: 1803-13.